Biopharmaceutical company Syncromune has had its lead-candidate for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) granted Fast Track designation by the FDA. Syncromune’s SYNC-T SV-102 therapy is a personalised treatment that comprises of an in situ vaccine via partial oncolysis of a tumour followed by intratumoral infusion of the SV-102 fixed-dose multi-target biologic drug into the […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!